SPONSORSHIP OF CONGRESSES AND EVENTS

When a pharmaceutical Company (Italian Affiliate or MAH) intends to sponsor a meeting or a congress attended by Italian Healthcare…

READ

UPDATES FROM THE ITALIAN MOH ON EU REGULATION 2017/745

The EU Regulation 2017/745 on medical devices (MDR) came into force in May 2021 but there are still several points…

READ

THE ITALIAN DRUG TRACEABILITY SYSTEM

The traceability project put in place by the Italian MoH is an instrument to uniquely identify every single package of…

READ

NEW AIFA DISPOSITIONS ABOUT THE TIMING FOR THE SUBMISSION OF VARIATIONS TO IMPLEMENT PRAC RECOMMENDATIONS

AIFA recently published a new press release with some clarifications on the timing for the submission of variations to implement PRAC…

READ

CLINICAL TRIALS – ENTRY INTO FORCE OF REGULATION (EU) 536/2014 AND CLINICAL TRIALS INFORMATION SYSTEM

The European Commission has confirmed that the entry into force of the Clinical Trials Regulation (EU) No 536/2014 and the…

READ

ADVANCED THERAPY MEDICINAL PRODUCTS IN ITALY

ATMP (Advanced Therapy Medicinal Products) are medicines for human use that are based on genes, tissues or cells and offer…

READ

RPIS IN PIPS AND WAIVERS

The use of the research product identifier (RPI) is used to make EMA processes more efficient by creating a single…

READ

PILOT PROGRAM EMA-FDA PARALLEL SCIENTIFIC ADVICE FOR HYBRID/COMPLEX GENERIC PRODUCTS

The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have established a pilot program, starting from…

READ

COMMUNICATION AND ADVERTISING FOR OTC AND SOP MEDICINAL PRODUCTS IN ITALY

Communication and advertising activities for OTC and SOP medicinal products addressed to the public are subject to specific rules, with…

READ

CONVERTING CENTRALLY AUTHORISED PRODUCTS (CAPS) TO UK MARKETING AUTHORISATIONS (MAS)

After Brexit became effective on 1st January 2021, all existing EU product MAs obtained through Centralized procedure (CAP) have been…

READ